A new wave of cancer treatments is looking promising for the future of oncologic care.

The ovarian cancer drug RC88, which is made by the Chinese biopharmaceutical company RemeGen, received FDA approval for Phase 2 clinical trials earlier this month.

The drug received fast-track designation (FTD) for the treatment of “platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancers,” the company confirmed to Fox News Digital.

It’s important that ADCs are continuously studied, Slomovitz noted, as the bar for approval is “getting higher and higher.”

He added, “The good news is, we’re making progress.”

For more Health articles, visit foxnews.com/health.

Angelica Stabile is a lifestyle writer for Fox News Digital.